Related Experiment Video
Updated: Dec 28, 2025
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Microvasculopathy and soft tissue calcification in mice are governed by fetuin-A, magnesium and pyrophosphate
Anne Babler1, Carlo Schmitz1, Andrea Buescher1
1Helmholtz Institute for Biomedical Engineering, Biointerface Lab, RWTH Aachen University Hospital, Aachen, Germany.
Abstract:
Calcifications can disrupt organ function in the cardiovascular system and the kidney, and are particularly common in patients with chronic kidney disease (CKD). Fetuin-A deficient mice maintained against the genetic background DBA/2 exhibit particularly severe soft tissue calcifications, while fetuin-A deficient C57BL/6 mice remain healthy. We employed molecular genetic analysis to identify risk factors of calcification in fetuin-A deficient mice. We sought to identify pharmaceutical therapeutic targets that could be influenced by dietary of parenteral supplementation. We studied the progeny of an intercross of fetuin-A deficient DBA/2 and C57BL/6 mice to identify candidate risk genes involved in calcification. We determined that a hypomorphic mutation of the Abcc6 gene, a liver ATP transporter supplying systemic pyrophosphate, and failure to regulate the Trpm6 magnesium transporter in kidney were associated with severity of calcification. Calcification prone fetuin-A deficient mice were alternatively treated with parenteral administration of fetuin-A dietary magnesium supplementation, phosphate restriction, or by or parenteral pyrophosphate. All treatments markedly reduced soft tissue calcification, demonstrated by computed tomography, histology and tissue calcium measurement. We show that pathological ectopic calcification in fetuin-A deficient DBA/2 mice is caused by a compound deficiency of three major extracellular and systemic inhibitors of calcification, namely fetuin-A, magnesium, and pyrophosphate. All three of these are individually known to contribute to stabilize protein-mineral complexes and thus inhibit mineral precipitation from extracellular fluid. We show for the first time a compound triple deficiency that can be treated by simple dietary or parenteral supplementation. This is of special importance in patients with advanced CKD, who commonly exhibit reduced serum fetuin-A, magnesium and pyrophosphate levels.
Insights
Severe soft tissue calcification in mice is caused by combined deficiencies in fetuin-A, magnesium, and pyrophosphate. Supplementation with these factors effectively reduced calcification, offering potential therapeutic strategies for chronic kidney disease patients.
Area of Science:
- Nephrology
- Biochemistry
- Genetics
Background:
- Calcifications impair cardiovascular and kidney function, especially in chronic kidney disease (CKD).
- Fetuin-A deficiency causes severe calcification in DBA/2 mice but not C57BL/6 mice.
- Understanding genetic risk factors and therapeutic targets for calcification is crucial.
Purpose of the Study:
- Identify genetic risk factors for calcification in fetuin-A deficient mice.
- Explore dietary and parenteral supplementation as therapeutic interventions.
- Investigate the role of compound deficiencies in pathological calcification.
Main Methods:
- Molecular genetic analysis of intercrossed DBA/2 and C57BL/6 mice.
- Assessment of Abcc6 and Trpm6 gene mutations.
- Treatment of calcification-prone mice with fetuin-A, magnesium, or pyrophosphate supplementation.
- Evaluation of calcification using computed tomography, histology, and calcium measurements.
Main Results:
- A hypomorphic mutation in Abcc6 and dysregulation of Trpm6 were associated with calcification severity.
- Parenteral fetuin-A, dietary magnesium, or pyrophosphate supplementation significantly reduced soft tissue calcification.
- Pathological calcification resulted from a compound deficiency of fetuin-A, magnesium, and pyrophosphate.
Conclusions:
- Fetuin-A, magnesium, and pyrophosphate act as critical inhibitors of calcification.
- A triple deficiency of these factors drives severe ectopic calcification.
- Dietary or parenteral supplementation offers a promising therapeutic approach for calcification, particularly in CKD patients with low levels of these factors.
